Stocktoria
Taysha Gene Therapies, Inc. TSHA
Taysha Gene Therapies, Inc. (TSHA) earns a Piotroski F-score of 4/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $9.8M at a -1115.3% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 4/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.868 |
| Retained earnings / assets | -2.072 |
| EBIT / assets | -0.322 |
| Equity / liabilities | 2.562 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| TSHA | Taysha Gene Therapies, Inc. | 4/9 | -0.53 | — | — |
| CRIS | CURIS INC | 2/9 | — | — | -13.4% |
| ACOG | Alpha Cognition Inc. | 2/9 | 3.69 | — | — |
| CRBU | Caribou Biosciences, Inc. | 2/9 | -9.88 | — | — |
| ELUT | ELUTIA INC. | 4/9 | -8.05 | 0.8 | -15% |
| FATE | FATE THERAPEUTICS INC | 1/9 | -13.3 | — | -51.2% |
| DBVT | DBV Technologies S.A. | 3/9 | -2.63 | — | — |
About Taysha Gene Therapies, Inc.
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
FAQ
Is TSHA financially healthy?
Taysha Gene Therapies, Inc.'s Piotroski F-score is 4/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does TSHA pay a dividend?
No, Taysha Gene Therapies, Inc. does not currently pay a dividend.
How profitable is TSHA?
In FY2025, Taysha Gene Therapies, Inc. had a net margin of -1115.3% and a return on equity of -44.1%.
What is the analyst price target for TSHA?
The average Wall-Street price target for Taysha Gene Therapies, Inc. is $12.85, about 100.6% above the recent price, from 13 analysts (consensus: strong buy).
Is TSHA a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Taysha Gene Therapies, Inc.: a Piotroski F-score of 4/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.